USP and Public Policy
Left
Refine Your Search
The United States Pharmacopeia (USP) is pleased to offer its support for the “Mapping America’s Pharmaceutical Supply Act” (S. 2364), or the MAPS Act.
Learn More
USP supports a comprehensive public policy framework to combat substandard and falsified medicines, including advancing stewardship of quality pharmaceutical products and practices, and building the…
Learn More
USP is pleased to submit feedback to the Senate HELP Committee on the bipartisan discussion draft to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA).
Learn More
USP is please to provide a response to the Senate Committee on Health, Education, Labor, and Pensions (HELP) Request for Information on policies related to the Pandemic and All-Hazards Preparedness…
Learn More
USP appreciate the opportunity to respond to the request for information (RFI) from the Office of Science and Technology Policy (OSTP) on the National Biotechnology and Biomanufacturing Initiative.
Learn More
A resilient supply chain withstands acute disruptions so that safe, effective, and quality medicines can be supplied to patients around the globe, in adequate quantities, when they are needed. Poster…
Learn More
USP appreciates the opportunity to provide comments on ACIL’s “Guide to a Harmonized National Cannabis Laboratory Accreditation Program.
Learn More
USP supports leadership on the release of the discussion draft of the “Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act” (“PREVENT Pandemics Act."
Learn More
USP urged the California Assembly to consider highlighting the need for quality specifications as part of the regulatory framework for California Assembly Bill AB-45 and Senate Bill SB-235, “…
Learn More
USP greatly appreciate the opportunity to provide feedback on the Cannabis Administration and Opportunity Act (CAOA) Discussion Draft.
Learn More